Halozyme Therapeutics Inc (HALO)

Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari

Conto economico

Trimestrale

*Tutti i numeri sono espressi in milioni

Data di fine periodo	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Durata del periodo	3 mesi	3 mesi	3 mesi	3 mesi	3 mesi
Revenues	14.85% 195.88	230.04	216.03	221.04	162.14
Cost Of Revenue	45.83% 28.33	52.30	54.82	50.07	35.17
Gross Profit	5.73% 167.55	177.74	161.21	170.97	126.97
Operating Expenses	6.12% 72.01	76.71	72.93	76.51	73.17
Interest Income/Expense	13.66% 4.507	5.22	4.505	4.494	4.543
Benefits Costs and Expenses	22.51% 99.85	128.86	114.27	127.88	109.91
Costs And Expenses	22.22% 100.34	129.00	127.75	126.58	108.34
Operating Income/Loss	5.44% 95.54	101.03	88.28	94.46	53.80
Income/Loss From Continuing Operations Before Tax	5.09% 96.03	101.17	101.76	93.16	52.24
Income Tax Expense/Benefit	21.65% 19.20	15.79	19.92	18.40	12.62
Income/Loss From Continuing Operations After Tax	10.03% 76.82	85.39	81.84	74.75	39.62
Net Income/Loss	10.03% 76.82	85.39	81.84	74.75	39.62
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	13,200% 126.94	-0.969	131.97	131.73	135.03
Diluted Average Shares	12,541% 128.89	-1.036	134.08	133.54	137.90
Basic Earnings Per Share	6.15% 0.61	0.65	0.62	0.57	0.29
Diluted Earnings Per Share	7.69% 0.60	0.65	0.61	0.56	0.29
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-